


THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:

- A composition comprising an activity-enhancing amount of one or more saponins in combination with one or more sapogenins, and having an enhanced anti-cancer activity.
- 2. The composition according to claim 1, wherein the saponins and sapogenins are selected from the group comprising: Rh2, Rg3, aglycon protopanaxatriol, and aglycon protopanaxadiol.
- 3. The composition according to claim 2, comprising about 70% sapogenins, about 8% Rh2, and about 2% Rg3.
- The composition according to claim 2, comprising between about 1-90% each of Rh2, aglycon protopanaxatriol, and aglycon protopanaxadiol.
- 5. The composition according to claim 4, comprising between about 1-50% of Rh2, between about 5-40% of aglycon protopanaxatriol, and between about 5-75% of aglycon protopanaxadiol.
- The composition according to claim 5, comprising between about 5-40% of Rh2, between about 5-40% of aglycon protopanaxatriol, and between about 10-70% of aglycon protopanaxadiol.
- The composition according to any one of claims claims 1 to 6, wherein one or more of said saponins and sapogenins are extracted from plant material.
- 8. The composition according to claim 7, wherein said plant material is derived from one or more plant from the genus *Panax*.
- 9. The composition according to claim 8, wherein said plant is Panax ginseng.


7-08-2004



- 10. The composition according to claim 8, wherein said plant is Panax quinquefolium.
- 11. The composition according to claim 8, wherein said plant is Panax notoginseng.
- 12. The composition according to any one of claims 1-11, wherein one or more of said saponins and sapogenins are synthetic.
- 13. A pharmaceutical formulation for the treatment of cancer, comprising a therapeutically effective amount of the composition according to any one of claims 1-12 and a pharmacologically acceptable carrier.
- 14. A non-pharmaceutical formulation for the treatment of cancer, comprising a therapeutically effective amount of the composition according to any one of claims 1-12 and a pharmacologically acceptable carrier.
- 15. The formulation according to claim 13 or 14, wherein the formulation is in an orally administrable form.
- 16. The formulation according to claim 13 or 14, wherein the formulation is in an injectable form.
- 17. The formulation according to claim 13 or 14, wherein the formulation is in a topically applicable form.
- 18. The formulation according to claim 13 or 14, wherein said therapeutically effective amount comprises a dosage of between 0.01 mg to 1000 mg of Rh2 per kg bodyweight per day.
- 19. The formulation according to claim 13 or 14, wherein said therapeutically effective amount comprises a dosage of between 0.01 mg to 1000 mg of aglycon protopanaxatriol per kg bodyweight per day.

- 20. The formulation according to claim 13 or 14, wherein said therapeutically effective amount comprises a dosage of between 0.01 mg to 1000 mg of aglycon protopanaxadiol per kg bodyweight per day.
- 21. Use of the composition according to any one of claims 1-12 for the treatment of cancer in a mammal.
- 22. The use according to claim 21, wherein said cancer is selected from the group consisting of glioma tumor, melanoma, breast cancer, pancreatic cancer, brain tumor, intestinal and gastric cancers, prostate cancer, and lung cancer.
- 23. The use according to claim 21, wherein said cancer is selected from the group consisting of stomach cancer, esophagus cancer, colon and rectum cancer, ovary cancer, liver cancer, kidney cancer, larynx cancer, bone cancer, multiple myeloma, bladder cancer, cancer in body of uterus, oral cavity cancer, thyroid cancer, cervix cancer, testis cancer, non-Hodgkin's lymphoma, leukemia, Hodgkin's disease, skin cancer, and soft tissue cancer.
- 24. The use according to claim 21, wherein said cancer is a multi-drug resistant cancer.
- 25. The use according to claim 24, wherein said multi-drug resistant cancer is a primary cancer selected from the group consisting of cancers of muscle, bone or connective tissues, the skin, brain, lungs, sex organs, the lymphatic or renal systems, mammary or blood cells, liver, the digestive tract, pancreas and thyroid or adrenal glands, including solid tumors, cancers of the ovary, breast, brain, prostate, colon, stomach, kidney or testicles, Kaposi's sarcoma, cholangioma, chorioma, neuroblastoma, Wilms' tumor, Hodgkin's disease, melanomas, multiple myelomas, lymphatic leukemias and acute or chronic granulocytic lymphomas.





- 26. The use according to claim 24, wherein said multi-drug resistant cancer is a recurrent cancer selected from the group consisting of pancreatic cancer, lung cancer, stomach cancer, esophagus cancer, colon and rectum cancer, brain cancer, ovary cancer, liver cancer, kidney cancer, larynx cancer, bone cancer, multiple myeloma, melanoma, breast cancer, prostate cancer, bladder cancer, cancer in body of uterus, oral cavity cancer, thyroid cancer, cervix cancer, testis cancer, non-Hodgkin's lymphoma, leukemia, Hodgkin's disease, skin cancer, and soft tissue cancer.
- 27. The use according to any one of claims 21-26, wherein said composition is used in combination with one or more other chemotherapeutic agents.
- 28. The use according to any one of claims 21-26, wherein said mammal is a human.
- 29. The use of a composition according to any one of claims 1-12 in the manufacture of a medicament for the treatment of cancer.
- 30. A pharmaceutical kit for the treatment of cancer in a mammal comprising the composition according to any one of claims 1-12 and one or more containers.